Skip to main content
. 2021 Dec 13;12:736860. doi: 10.3389/fphar.2021.736860

TABLE 1.

Input parameters.

Parameters Mean Range Distribution Reference
Survival model of PFS in the full cohort
 Nivolumab + cabozantinib Shape = 1.569; Scale = 15.064 Log-logistic Choueiri et al. (2015)
 Sunitinib Shape = 1.646; Scale = 8.269 Log-logistic Choueiri et al. (2015)
 Axitinib Shape = 1.4633; Scale = 6.6318 Log-logistic National Cancer Institute, (2021)
 Sorafenib Shape = 2.281 Exponential (Bhatt and Finelli, 2014; Amzal et al., 2017)
 OS in the best support care Shape = 1.613; Scale = 13.857 Log-logistic Sarfaty et al. (2018)
Probability of treatment discontinuation as a result of AE (%)
 Nivolumab + cabozantinib 19.7 Beta Fisher et al. (2013)
 Sunitinib 16.9 Beta Fisher et al. (2013)
 Axitinib 8.49 Beta National Cancer Institute, (2021)
 Sorafenib 18.11 Beta (Bhatt and Finelli, 2014; Amzal et al., 2017)
Probability of treatment mortality as a result of AE (%)
 Nivolumab + cabozantinib 0.31 Beta Choueiri et al. (2015)
 Sunitinib 0.61 Beta Choueiri et al. (2015)
 Axitinib 0 National Cancer Institute, (2021)
 Sorafenib 0.7 Beta (Bhatt and Finelli, 2014; Amzal et al., 2017)
 Probability of background death Cella, (2011)
Drug cost
 Nivolumab 240 mg 6,849.84 5,479.87–8,219.81 Gamma Casciano et al. (2011)
 Cabozantinib 60 mg 491.30 393.04–589.56 Gamma Motzer et al. (2018)
 Sunitinib 50 mg 623.08 498.46–747.70 Gamma Motzer et al. (2018)
 Axitinib 5 mg 265.05 212.04–318.06 Gamma Powles et al. (2020)
 Sorafenib 200 mg 174 139.20–208.80 Gamma Motzer et al. (2019)
 Cost of best support care 1,256 1,022–1,489 Gamma Motzer et al. (2018)
Management of AEs
 Nivolumab + cabozantinib 1,214.68 971.74–1,457.61 Gamma (Choueiri et al., 2015; Choueiri et al., 2017)
 Sunitinib 6,632.78 5,306.22–7,959.34 Gamma (Choueiri et al., 2015; Choueiri et al., 2017)
 Axitinib 4,660.34 3,728.27–5,592.41 Gamma (Motzer et al., 2015; Motzer et al., 2018; Choueiri et al., 2021; National Cancer Institute, 2021)
 Sorafenib 2,284.81 556.72–835.08 Gamma (Bhatt and Finelli, 2014; Amzal et al., 2017; Choueiri et al., 2021)
Administration cost
 IV infusion, single or initial drug (≤1 h) 148.3 118.64–177.93 Gamma National Comprehensive Cancer Network, (2021)
Utilities
 First-line treatment 0.82 0.65–0.98 Beta Choueiri et al. (2017)
 Second-line treatment 0.77 (SD: 0.24) 0.616–0.924 Beta Neumann et al. (2014)
 Third-line treatment 0.66 (SD: 0.30) 0.528–0.792 Beta Weinstein et al. (1996)
 Fourth-line treatment, BSC 0.494 0.403–0.570 Beta Rini et al. (2011)
 Disutility due to AEs (grade ≥3) 0.157 0.11–0.204 Beta Rini et al. (2020)
 Average patient weight (kg) 70 49.0–93.8 Beta Powles et al. (2020)

OS, overall survival; PFS, progression-free survival; AE, adverse event.